Anticoagulation Alone Versus Anticoagulation and Aspirin Following Transcatheter Aortic Valve Interventions (1:1)

Exclusion Criteria

• •The patient is participating in another study
• •The patient is in an exclusion period determined by a previous study
• •The patient or his/her representative refuses to sign the consent
• •It is impossible to correctly inform the patient or his/her representative
• •The patient is pregnant or breastfeeding
• •The patient has a contraindication (or an incompatible drug association) for a treatment used in this study
• •The patient had a coronary stent for less than 12 months
• •The patient does not require treatment with aspirin or any other antiplatelet agent
• •The patient has a history of aspirin allergy
• •High bleeding risk; such as platelets \<50,000 / mm3 during screening, Hb \<8.5 g / dL, history of intracranial hemorrhage or subdural hematoma, major surgery, parenchymal organ biopsy or severe trauma within 30 days before inclusion, active gastrointestinal ulcer in the last 3 months;
• •History of Stroke in the last 3 months;
• •Moderate or severe liver affection associated with coagulopathy
• •Active infectious endocarditis
• •Active tumor treated at the time of inclusion associated with expected survival less than one year
• •Not following countraindications specific to the molecules used fo the patients receiving DOAC